In particular, T-cell expansion or persistence is less well correlated with lymphoma response than in B-ALL. 19,20 Instead, baseline tumor burden, characteristics of the CART19 product (memory state ...

Epcoritamab is a CD3xCD20-directed T-cell–engaging bispecific antibody that is indicated for patients with relapsed/refractory diffuse LBCL (DLBCL) not otherwise specified (NOS), including DLBCL ...

Like its Big Pharma peers, Cullinan Therapeutics is turning to China for novel drug candidates. The company on Wednesday inked a licensing deal with Genrix Bio, gaining global rights to the ...

One of the major challenges in CAR-T therapy is finding a target that’s specific to the tumor cell and absent from healthy cells so that the T cells are directed at the tumor. The target of CER-1236, ...

About Multiple Myeloma Multiple myeloma is a blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.2 In multiple myeloma, these malignant ...

The CAR T cell therapy, called NXC-201, targets a protein called BCMA, which is expressed on the surface of amyloid plasma cells and drives cancer growth. In the first 10 patients to receive the ...

8505Background: JNJ-68284528 (JNJ-4528) is a chimeric antigen receptor T (CAR-T) cell therapy containing 2 BCMA-targeting single-domain antibodies. Here we present updated CARTITUDE-1 ... Hematologic ...